Results 161 to 170 of about 1,978 (184)

Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine

Drug Delivery and Translational Research, 2011
We describe the engineering of a degradable intravaginal ring (IVR) for the delivery of the potent HIV-1 reverse transcriptase inhibitor dapivirine. The degradable polymer used in fabricating the device incorporated poly(caprolactone) ester blocks in a poly(tetramethylene ether) glycol ABA type polyurethane backbone.
Manpreet, Kaur, Kavita M, Gupta, Azadeh E, Poursaid, Prasoona, Karra, Alamelu, Mahalingam, Hyder A, Aliyar, Patrick F, Kiser   +6 more
openaire   +2 more sources

Safety and Availability of Dapivirine (TMC120) Delivered from an Intravaginal Ring

AIDS Research and Human Retroviruses, 2009
Vaginal delivery of 200 mg or 25 mg dapivirine from intravaginal rings (IVRs) was evaluated over a 7-day period in two phase 1 safety trials (IPM001 and IPM008, respectively) in a total of 25 healthy women 19 to 46 years of age. The IVR was generally safe and well tolerated with similar adverse events observed in the placebo and dapivirine groups ...
Romano, J., Variano, B., Coplan, P., Roey, J. Van, Douville, K., Rosenberg, Z., Temmerman, Marleen, Verstraelen, H., Bortel, L. Van, Weyers, S., Mitchnick, M.   +10 more
openaire   +3 more sources

Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial

AIDS and Behavior, 2022
MTN-025/HOPE was an open-label trial of the dapivirine vaginal ring conducted in four African countries between 2016 and 2018. Women were first offered one ring monthly (at baseline, months 1 and 2), thereafter, transitioned to a more applicable real-world dispensation schedule, - 3 rings quarterly (at months 3, 6 and 9).
Brenda Gati Mirembe, Maria Valdez Cabrera, Ariane van der Straten, Rita Nakalega, Mandy Cobbing, Nyaradzo M. Mgodi, Thesla Palanee-Phillips, Ashley J. Mayo, Sufia Dadabhai, Leila E. Mansoor, Samantha Siva, Gonasagrie Nair, Lameck Chinula, Carolyne A. Akello, Clemensia Nakabiito, Lydia E. Soto-Torres, Jared M. Baeten, Elizabeth R. Brown   +17 more
openaire   +2 more sources

Development of Reservoir Vaginal Rings Containing Dapivirine or Hormonal Contraceptive Steroids

AIDS Research and Human Retroviruses, 2014
Background: By extending the use duration of vaginal rings (VRs) the overall production cost per patient per month can be greatly reduced. Matrix-type ring designs produce an initial burst of drug release and concentrations during the burst must be maintained within safe limits. This constrains both the maximum drug load and in turn the use duration of
McCoy, Clare, Boyd, Peter, Fetherston, Susan, Major, Ian, Murphy, Diarmaid, Brimer, Andrew, Holt, Jonathon, Devlin, Brid, Blanda, Wendy, Derrick, Tiffany, Gimour, Chris, Nuttall, Jeremy, Malcolm, Karl   +12 more
openaire   +2 more sources

A Combination Vaginal Ring Releasing Dapivirine and Darunavir

AIDS Research and Human Retroviruses, 2014
Karl Malcolm, Diarmaid Murphy, Delphine Desjardins, Nathalie Dereuddre-Bosquet, Patricia Brochard, Ludivine Perrot, Alain Pruvost, Roger Le Grand, Ole Lagatie, Leen Vanhooren, Maxim Feyaerts, Jens Van Roey   +11 more
openaire   +1 more source

Breast milk dapivirine pharmacokinetics, estimated infant exposure, and safety during dapivirine intravaginal ring use among lactating women

American Journal of Obstetrics and Gynecology, 2017
Noguchi L, Beigi R, Biggio J, Marzinke M, Kelly C, Bunge K, Scheckter R, Piper J, Hillier S, Nel A, Hendrix C   +10 more
openaire   +1 more source

Dapivirine ring reduces HIV acquisition

Nature Reviews Urology, 2016
openaire   +1 more source

Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study

Lancet HIV,the, 2021
Nyaradzo M Mgodi, Ashley J Mayo, Brenda Mirembe   +2 more
exaly  

Safety of dapivirine vaginal rings during breastfeeding

The Lancet HIV
Katrina F, Ortblad, Kenneth, Ngure
openaire   +2 more sources

Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study

Lancet HIV,the, 2021
Allison Carter, Jennifer F Morton, Sylvia Kusemererwa   +2 more
exaly